Clinical Trial

A Multicenter, Prospective, Phase III Clinical Study of Proton Intensity-modulated Radiotherapy Versus Photon Intensity-modulated Radiotherapy for Untreated Non-metastatic Nasopharyngeal Carcinoma

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Proton therapy for nasopharyngeal carcinoma can reduce radiotherapy-related toxic reactions, and some retrospective studies have found that proton therapy improves the survival of patients with nasopharyngeal carcinoma. However, high-level prospective clinical evidence is still lacking. This study aims to investigate the efficacy and side effects of proton therapy compared with photon intensity-modulated radiotherapy for nasopharyngeal carcinoma through a multicenter, prospective, phase III clinical trial, providing more high-quality evidence-based medical evidence for proton therapy of nasopharyngeal carcinoma.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-07-09
Trial Details
NCT Number NCT07578727
Lead Sponsor Guangzhou Concord Cancer Center
Conditions Nasopharyngeal Carcinoma (NPC)
Enrollment 504 participants
Start Date 2026-07-01
Primary Completion 2028-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-08